FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743755800> ?p ?o ?g. }

• W2743755800 endingPage "72196" @default.
• W2743755800 startingPage "72182" @default.
• W2743755800 abstract "// Yingjun Wang 1 , Mingzhi Zhang 1 , Huanan Xu 2 , Yifei Wang 3 , Zhaoming Li 1 , Yu Chang 1 , Xinhuan Wang 1 , Xiaorui Fu 1 , Zhiyuan Zhou 1 , Siyuan Yang 1 , Bei Wang 1 and Yufeng Shang 1 1 Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China 2 Department of Anorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 3 Department of Ultrasonography, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China Correspondence to: Mingzhi Zhang, email: Zhangmingzhi_11@163.com Keywords: lncRNAs, diffuse large B-cell lymphoma, lncRNA PANDA, p53, MAPK/ERK Received: June 30, 2017      Accepted: July 26, 2017      Published: August 07, 2017 ABSTRACT Diffuse large B-cell lymphoma (DLBCL) is one of the leading causes of cancer-related mortality, and responds badly to existing treatment. Thus, it is of urgent need to identify novel prognostic markers and therapeutic targets of DLBCL. Recent studies have shown that long non-coding RNAs (lncRNAs) play an important role in the development of cancer. By using the next generation HiSeq sequencing assay, we determined lncRNAs exhibiting differential expression between DLBCL patients and healthy controls. Then, RT-qPCR was performed for identification in clinical samples and cell materials, and lncRNA PANDA was verified to be down-regulated in DLBCL patients and have considerable diagnostic potential. In addition, decreased serum PANDA level was correlated to poorer clinical outcome and lower overall survival in DLBCL patients. Subsequently, we determined the experimental role of lncRNA PANDA in DLBCL progression. Luciferase reporter assay and chromatin immunoprecipitation assay suggested that lncRNA PANDA was induced by p53 and p53 interacts with the promoter region of PANDA. Cell functional assay further indicated that PANDA functioned as a tumor suppressor gene through the suppression of cell growth by a G0/G1 cell cycle arrest in DLBCL. More importantly, Cignal Signal Transduction Reporter Array and western blot assay showed that lncRNA PANDA inactivated the MAPK/ERK signaling pathway. In conclusion, our integrated approach demonstrates that PANDA in DLBCL confers a tumor suppressive function through inhibiting cell proliferation and silencing MAPK/ERK signaling pathway. Thus, PANDA may be a promising therapeutic target for patients with DLBCL." @default.
• W2743755800 created "2017-08-17" @default.
• W2743755800 creator A5004301598 @default.
• W2743755800 creator A5010480280 @default.
• W2743755800 creator A5019544133 @default.
• W2743755800 creator A5020383361 @default.
• W2743755800 creator A5029941351 @default.
• W2743755800 creator A5031431608 @default.
• W2743755800 creator A5050257179 @default.
• W2743755800 creator A5069266579 @default.
• W2743755800 creator A5070256347 @default.
• W2743755800 creator A5080214203 @default.
• W2743755800 creator A5089378544 @default.
• W2743755800 creator A5090047434 @default.
• W2743755800 date "2017-08-07" @default.
• W2743755800 modified "2023-10-16" @default.
• W2743755800 title "Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway" @default.
• W2743755800 cites W1531414226 @default.
• W2743755800 cites W1537007105 @default.
• W2743755800 cites W2012116432 @default.
• W2743755800 cites W2012411040 @default.
• W2743755800 cites W2016969330 @default.
• W2743755800 cites W2029919331 @default.
• W2743755800 cites W2062296158 @default.
• W2743755800 cites W2083690675 @default.
• W2743755800 cites W2084308291 @default.
• W2743755800 cites W2084596378 @default.
• W2743755800 cites W2095916340 @default.
• W2743755800 cites W2100441605 @default.
• W2743755800 cites W2116168949 @default.
• W2743755800 cites W2117426190 @default.
• W2743755800 cites W2131940231 @default.
• W2743755800 cites W2133832725 @default.
• W2743755800 cites W2136060045 @default.
• W2743755800 cites W2141337702 @default.
• W2743755800 cites W2150695488 @default.
• W2743755800 cites W2166810745 @default.
• W2743755800 cites W2167571754 @default.
• W2743755800 cites W2169446357 @default.
• W2743755800 cites W2171488406 @default.
• W2743755800 cites W2187367250 @default.
• W2743755800 cites W2219153045 @default.
• W2743755800 cites W2220034225 @default.
• W2743755800 cites W2300667207 @default.
• W2743755800 cites W2316868006 @default.
• W2743755800 cites W2344181526 @default.
• W2743755800 cites W2466016379 @default.
• W2743755800 cites W2565108057 @default.
• W2743755800 cites W2579268832 @default.
• W2743755800 cites W2625442315 @default.
• W2743755800 doi "https://doi.org/10.18632/oncotarget.20053" @default.
• W2743755800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641121" @default.
• W2743755800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069778" @default.
• W2743755800 hasPublicationYear "2017" @default.
• W2743755800 type Work @default.
• W2743755800 sameAs 2743755800 @default.
• W2743755800 citedByCount "39" @default.
• W2743755800 countsByYear W27437558002018 @default.
• W2743755800 countsByYear W27437558002019 @default.
• W2743755800 countsByYear W27437558002020 @default.
• W2743755800 countsByYear W27437558002021 @default.
• W2743755800 countsByYear W27437558002022 @default.
• W2743755800 countsByYear W27437558002023 @default.
• W2743755800 crossrefType "journal-article" @default.
• W2743755800 hasAuthorship W2743755800A5004301598 @default.
• W2743755800 hasAuthorship W2743755800A5010480280 @default.
• W2743755800 hasAuthorship W2743755800A5019544133 @default.
• W2743755800 hasAuthorship W2743755800A5020383361 @default.
• W2743755800 hasAuthorship W2743755800A5029941351 @default.
• W2743755800 hasAuthorship W2743755800A5031431608 @default.
• W2743755800 hasAuthorship W2743755800A5050257179 @default.
• W2743755800 hasAuthorship W2743755800A5069266579 @default.
• W2743755800 hasAuthorship W2743755800A5070256347 @default.
• W2743755800 hasAuthorship W2743755800A5080214203 @default.
• W2743755800 hasAuthorship W2743755800A5089378544 @default.
• W2743755800 hasAuthorship W2743755800A5090047434 @default.
• W2743755800 hasBestOaLocation W27437558001 @default.
• W2743755800 hasConcept C104317684 @default.
• W2743755800 hasConcept C121608353 @default.
• W2743755800 hasConcept C126322002 @default.
• W2743755800 hasConcept C143998085 @default.
• W2743755800 hasConcept C2778559949 @default.
• W2743755800 hasConcept C2779338263 @default.
• W2743755800 hasConcept C502942594 @default.
• W2743755800 hasConcept C54355233 @default.
• W2743755800 hasConcept C57074206 @default.
• W2743755800 hasConcept C62203573 @default.
• W2743755800 hasConcept C62478195 @default.
• W2743755800 hasConcept C67705224 @default.
• W2743755800 hasConcept C71924100 @default.
• W2743755800 hasConcept C86803240 @default.
• W2743755800 hasConceptScore W2743755800C104317684 @default.
• W2743755800 hasConceptScore W2743755800C121608353 @default.
• W2743755800 hasConceptScore W2743755800C126322002 @default.
• W2743755800 hasConceptScore W2743755800C143998085 @default.
• W2743755800 hasConceptScore W2743755800C2778559949 @default.
• W2743755800 hasConceptScore W2743755800C2779338263 @default.
• W2743755800 hasConceptScore W2743755800C502942594 @default.

• next